NCT05424692Recruiting
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined with Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 4 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 3 May 2022
- Start date
- 1 Sept 2021
- Primary completion date
- 1 Sept 2025
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT05424692
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 Sept 2021 to the primary completion date, 1 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other malignant tumors
- Suffering from serious mental and nervous system diseases
Other
- Patients diagnosed with metastasis
- Patients who cannot obtain tumor samples
- Pregnant and lactating women
- Patients with poor compliance
- Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment
- The researchers believe that patients should not be selected for this study
Who the study is looking for
- Age 18 \~ 75 years old, regardless of gender
- Patients with colorectal cancer diagnosed by histopathology or cytology
- Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy
- Having at least one assessable tumor focus
- ECoG physical condition score ≤ 2 points
- Voluntarily participate and sign informed consent
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.